SEC 13F Intelligence

Managers / Q2 2025

Camber Capital Management LP

CIK 0001444043 · 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON, MA, 02199 · 617-717-6600

Reported Value
$1.1B
Q2 2025
Positions
25
Filings on Record
28
2019–present window
Filed
Aug 14, 2025
original filing

Summary

Camber Capital Management LP reported $1.1B in U.S.-listed holdings across 25 positions for Q2 2025.

Its largest position, ZBH, represents 8.6% of the portfolio.

Compared with Q1 2025, the fund opened 4 new positions and exited 10.

Portfolio Metrics

Turnover
+6.7%
vs prior filed quarter
Top-10 Concentration
+53.2%
share of reported value
Largest Position
+8.6%
Zimmer Biomet
New / Exited
4 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.0BQ2 ’19: $2.1BQ3 ’19: $1.9BQ4 ’19: $2.0BQ4 ’19Q1 ’20: $1.7BQ2 ’20: $1.7BQ3 ’20: $1.9BQ4 ’20: $2.8BQ4 ’20Q1 ’21: $2.9BQ2 ’21: $3.0BQ3 ’21: $3.2BQ4 ’21: $2.9BQ4 ’21Q1 ’22: $2.8BQ2 ’22: $2.3BQ3 ’22: $3.3BQ1 ’23: $3MQ1 ’23Q2 ’23: $3MQ3 ’23: $3MQ4 ’23: $4MQ1 ’24: $4MQ1 ’24Q2 ’24: $4MQ3 ’24: $3MQ4 ’24: $4MQ2 ’25: $1.1BQ2 ’25filingsflow.com

Portfolio Composition

By security type
Common Stock: 58.8%ETP: 29.0%Other: 8.6%ADR: 3.6%
  • Common Stock · 58.8% · $626M
  • ETP · 29.0% · $309M
  • Other · 8.6% · $92M
  • ADR · 3.6% · $38M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ICON PLCNEW+300.0K300.0K+$44M$44M
MRKMERCK & CO INCNEW+500.0K500.0K+$40M$40M
UNHUNITEDHEALTH GROUP INCNEW+100.0K100.0K+$31M$31M
APLSUSDAPELLIS PHARMACEUTICALS INCNEW+850.0K850.0K+$15M$15M
SPDR SER TRSOLD OUT−2.00M0−$162M$0
PTCTPTC THERAPEUTICS INCSOLD OUT−1.50M0−$76M$0
CITHE CIGNA GROUPSOLD OUT−200.0K0−$66M$0
QIAGEN NVSOLD OUT−1.40M0−$56M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2025

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ZBHZIMMER BIOMET HOLDINGS INChistory →COM8.56%$91M1.00M
2BAXBAXTER INTL INChistory →COM8.10%$86M2.85M
3HUMHUMANA INChistory →COM6.89%$73M300.0K
4CVSCVS HEALTH CORPhistory →COM6.80%$72M1.05M
5GMEDGLOBUS MED INChistory →CL A4.43%$47M800.0K
6ICON PLCSHS4.10%$44M300.0K
7ASCENDIS PHARMA A/SSPONSORED ADR4.05%$43M250.0K
8MRKMERCK & CO INChistory →COM3.72%$40M500.0K
9PFEPFIZER INChistory →COM3.41%$36M1.50M
10BMRNBIOMARIN PHARMACEUTICAL INChistory →COM3.10%$33M600.0K
11UNHUNITEDHEALTH GROUP INChistory →COM2.93%$31M100.0K
12VTRSVIATRIS INChistory →COM2.31%$25M2.75M
13B7SBROOKDALE SR LIVING INChistory →COM1.40%$15M2.15M
14ZIMVZIMVIE INChistory →COM1.40%$15M1.60M
15APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.38%$15M850.0K
16MYGNMYRIAD GENETICS INChistory →COM1.00%$11M2.00M
17EVHEVOLENT HEALTH INCCL A0.90%$10M850.0K
18CONCONCENTRA GROUP HOLDINGS PARCOMMON STOCK0.77%$8M400.0K
19INGNINOGEN INCCOM0.64%$7M975.0K
20DNLIDENALI THERAPEUTICS INCCOM0.53%$6M400.0K
21THERAVANCE BIOPHARMA INCCOM0.47%$5M450.0K
22ANABANAPTYSBIO INCCOM0.26%$3M125.0K
23EP3ORASURE TECHNOLOGIES INCCOM0.25%$3M900.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2025$1.1B25Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025Under review32May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$4M39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3M33Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$4M37Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$4M36May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4M38Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$3M38Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$3M41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review39Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.3B45Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.3B40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.8B37May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.9B39Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.2B39Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.0B34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B32May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B33Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.9B35Nov 16, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$1.7B30Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.7B29May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.0B29Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.9B34Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.1B31Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.0B28May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B36Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.